Related Experiment Videos
Efficient trial designs for studying combination antiretroviral treatments in patients with various resistance
P Gilbert1, V DeGruttola, S Hammer
1Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA. pgilbert@hsph.harvard.edu
Abstract:
Selecting antiretroviral therapies for human immunodeficiency virus type 1-infected persons is complicated by the availability of a vast number of potentially useful drug combinations and by extensive variation among patients in their resistance to various drugs. AIDS clinical trials have used designs in which a handful of drug regimens in a few patient classes can be compared. Here is proposed implementation of innovative designs with factorial structure that permit assessment of many treatment arms and patient classes in a single trial; when and how they can be appropriately used are discussed. These designs are efficient, permit systematic investigation of correlations between genetic mutations and in vivo drug resistance, and provide insight into important drug interactions in people that conventional designs are unable to provide. Through creative application of these designs, identification of superior drug combinations and the science of understanding in vivo joint drug dynamics and genotypic resistance will progress at an optimum pace.
Insights
Innovative clinical trial designs can efficiently compare many human immunodeficiency virus type 1 (HIV-1) drug combinations and patient groups. This approach accelerates the discovery of effective antiretroviral therapies and understanding of drug resistance.
Area of Science:
- Clinical Pharmacology
- Infectious Diseases
- Biostatistics
Background:
- Selecting effective antiretroviral therapies for HIV-1 is challenging due to numerous drug combinations and patient-specific drug resistance.
- Current AIDS clinical trials often compare limited drug regimens across few patient classes, hindering comprehensive evaluation.
Purpose of the Study:
- To propose and discuss the implementation of innovative factorial-structured clinical trial designs for HIV-1 therapy assessment.
- To enable the simultaneous evaluation of numerous treatment arms and patient classes within a single trial.
Main Methods:
- Implementation of innovative clinical trial designs with factorial structures.
- Systematic investigation of correlations between genetic mutations and in vivo drug resistance.
- Analysis of drug interactions in human subjects.
Main Results:
- Factorial designs efficiently assess multiple treatment arms and patient classes.
- These designs facilitate the systematic study of genotype-phenotype correlations in drug resistance.
- Provides insights into in vivo drug interactions not achievable with conventional designs.
Conclusions:
- Innovative factorial trial designs offer an efficient approach to advancing antiretroviral therapy selection for HIV-1.
- These designs accelerate the identification of superior drug combinations and enhance understanding of joint drug dynamics and genotypic resistance.